Study to Evaluate the Safety of ATR-04
← catalyst calendarSponsored by Azitra Inc. (industry) · AZTR — their whole pipeline →.
Phase
Phase 1/2
Status
Withdrawn
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
0actual
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
Business reasons.
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | Jan 2024 | estimated | When the study began enrolling |
| Primary completion | Jan 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jan 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2021-01-29 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-10-03 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Epidermal Growth Factor
- Papulopustular Rosacea
Interventions
- Drug: ATR-04
- Other: Placebo
Primary outcome
what the primary-completion date above is the date OFIncidence of Adverse Events (AEs), Serious Adverse Events (SAEs), incidence of abnormal laboratory values, abnormal physical exams and abnormal vital signs.
measured Through study completion, on average of 1 year
Permalink · AZTR's whole pipeline · Catalyst calendar · Every registered study · What changed